Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

INKT stock hub

MiNK Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

INKTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

54.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

INKT

In the news

Latest news · INKT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All INKT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

164

Groups with data

Currency

USD

Showing 164 of 164 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001840229
Company name	MiNK Therapeutics, Inc.
Country	United States
Country code	US
Cusip	603693201
Employees	23
Employees Change	-8%
Employees Change Percent	-25.81
Enterprise value	$46.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-10-15
Isin	US6036932019
Last refreshed	2026-05-10
Market cap	$54.8M
Market cap category	Micro-Cap
Price	$11.04
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	INKT
Website	https://minktherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-22.79%
FCF yield	-10.81%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-12.5M
Net Income Growth Years	0%
Profit Per Employee	$-543,229
ROA	-79.17
Roa5y	-88.25
ROCE	-1,047.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	49.63%
Cagr3y	-11.26%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$14.2M
Cash	$13.4M
Current Assets	$13.8M
Current Liabilities	$13M
Debt	$5.2M
Equity	$-14.2M
Liabilities	$28.5M
Long Term Assets	$390,869
Long Term Liabilities	$15.4M
Net Cash	$8.2M
Net Cash By Market Cap	$14.92
Tangible Book Value	$-14.2M
Tangible Book Value Per Share	$-3.02
WACC	6.26

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.06
Net Working Capital	$-7.4M
Quick ratio	1.03
Working Capital	$816,525

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.18%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	49.59%
200-day SMA	12.68
3Y total return	-30.13%
50-day SMA	11.03
50-day SMA vs 200-day SMA	50under200
All Time High	221.6
All Time High Change	-95.02%
All Time High Date	2021-11-01
All Time Low	4.56
All Time Low Change	142.11%
All Time Low Date	2025-01-28
ATR	0.86
Beta	0.47
Beta1y	-2.2
Beta2y	0.1
Ch YTD	-0.99
High	11.38
High52	76
High52 Date	2025-07-11
High52ch	-85.47%
Low	11
Low52	6.34
Low52 Date	2025-05-12
Low52ch	74.13%
Ma50ch	0.11%
Price vs 200-day SMA	-12.95%
RSI	46.43
RSI Monthly	34.58
RSI Weekly	48.03
Sharpe ratio	0.82x
Sortino ratio	8.34
Total Return	-13.18%
Tr YTD	-0.99
Tr1m	-4.83%
Tr1w	-4.91%
Tr3m	0.64%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.77
Operating Income	$-12.6M
Price target	$35
Price Target Change	$217

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,948,844%
Float Percent	39.24%
Shares Insiders	16.91%
Shares Institutions	3.11%
Shares Out	4,965,858
Shares Qo Q	5.47%
Shares Yo Y	13.18%
Short Float	4.95%
Short Ratio	1.45
Short Shares	1.94

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-8.6M
Average Volume	46,265.25x
Bv Per Share	-3.02
Ch1m	-4.83
Ch1w	-4.91
Ch1y	49.59
Ch3m	0.64
Ch3y	-30.13
Ch6m	-16.55
Change	-1.34%
Change From Open	0.36
Close	11.19
Days Gap	-1.7
Depreciation Amortization	181,745
Dollar Volume	92,097.6
Earnings Date	2026-05-15
Earnings Time	bmo
EBIT	$-12.6M
EBITDA	$-12.5M
EPS	$-2.93
F Score	2
FCF	$-5.9M
FCF EV Yield	-12.7x
FCF Per Share	$-1.19
Financing CF	14,721,897
Fiscal Year End	December
Founded	2,017
Ipr	-8
Iprfo	-90.83
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-31
Last Report Date	2025-12-31
Last Split Date	2025-01-28
Last Split Type	Reverse
Last10k Filing Date	2026-03-31
Ma150	11.95
Ma150ch	-7.61%
Ma20	11.91
Ma20ch	-7.29%
Net CF	8,783,300
Next Earnings Date	2026-05-15
Open	11
Optionable	No
Position In Range	10.53
Post Close	11.04
Postmarket Change Percent	-0.36
Postmarket Price	$11
Ppne	390,869
Price Date	2026-05-08
Relative Volume	0.18x
Share Based Comp	2,673,997
Tr6m	-16.55%
Us State	New York
Volume	8,342.2

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does INKT pay a dividend?

Capital-return profile for this ticker.

Performance

INKT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns INKT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.1%

Float: +39.2% of shares outstanding

Insider ownership

+16.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

INKT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.4

Neutral momentum band

Price vs 200-day MA

-12.9%

50/200-day relationship not available

Beta (5Y)

0.47

Less volatile than the market

Sharpe ratio

0.82

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About INKT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current INKT stock rating?

MiNK Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full INKT analysis?

The full report lives at /stocks/INKT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for INKT?

The latest report frames INKT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the INKT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.